Evolution of the Average Target: XP Inc.

Evolution of the Target Price: XP Inc.

Changes in Analyst Recommendations: XP Inc.

d4582b8a43cd33c9179c.k5l8TQjFmOjRI5-ttu3uQBhGL7_hvBc52DyrhxkUNc4._-49JF6i66KZFe7e-b2YGlATH8WDznFTtknFvytVQ6Dr7SolWaDe3odyyg~5a6005884498dcf62b5eef0c64d1f5b6
Aug. 31 Itau BBA Upgrades XP to Outperform From Market Perform, Adjusts PT to $22 From $19 MT
Apr. 02 UBS Adjusts Price Target on XP to $28 From $25, Maintains Buy Rating MT
Jan. 20 Jefferies Initiates XP at Buy With $22 Price Target MT
Dec. 16 UBS Adjusts XP Price Target to $25 From $23, Maintains Buy Rating MT
25-10-16 UBS Adjusts Price Target on XP to $23 From $24, Maintains Buy Rating MT
25-06-23 XP Shares Drop After Downgrade From Itau BBA MT
25-06-23 Itau BBA Downgrades XP to Market Perform From Outperform, Adjusts Price Target to $21 From $20 MT
25-06-10 UBS Adjusts XP Price Target to $24 From $17, Maintains Buy Rating MT
25-06-04 Goldman Sachs Upgrades XP to Buy From Neutral, $23 Price Target MT
25-05-13 XP Shares Rise After Morgan Stanley Upgrades to Overweight From Equalweight MT
25-05-13 Morgan Stanley Upgrades XP to Overweight From Equalweight, Adjusts Price Target to $24 From $18 MT
25-04-07 UBS Adjusts Price Target on XP to $17 From $16, Keeps Buy Rating MT
25-03-18 Itau BBA Initiates XP at Outperform With $20 Price Target MT
25-01-24 XP Shares Rise After Upgrade From UBS MT
25-01-24 UBS Upgrades XP to Buy From Neutral, Cuts Price Target to $16 From $19 MT
24-12-10 BofA Securities Downgrades XP to Neutral From Buy, Price Target is $16 MT
24-11-25 UBS Cuts Price Target on XP to $19 From $21, Maintains Neutral Rating MT
24-07-11 UBS Downgrades XP to Neutral From Buy, Cuts Price Target to $21 From $30 MT
24-07-05 Bradesco BBI Downgrades XP to Neutral From Outperform, Cuts Price Target to $19 From $31 MT
24-06-05 Citigroup Adjusts Price Target on XP to $27 From $29, Maintains Buy Rating MT
24-04-30 XP Shares Decline After Goldman Sachs Downgrade MT
24-04-30 Goldman Sachs Downgrades XP to Neutral From Buy, Cuts Price Target to $23 From $30 MT
24-04-23 Morgan Stanley Downgrades XP to Equalweight From Overweight, Adjusts Price Target to $24 From $31 MT
24-03-22 Citigroup Adjusts Price Target on XP to $29 From $28, Maintains Buy Rating MT
23-12-11 UBS Adjusts XP Price Target to $30 From $31, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+11.2%
+41.47%
+40.55%
+15.57%
+41.67%
+40.27%
- +6.5%
- - +45.51%
- - +47.37%
Average +32.23%
Weighted average by Cap. +32.68%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
107.45BRL
Average target price
119.47BRL
Spread / Average Target
+11.19%
High Price Target
134.16BRL
Spread / Highest target
+24.85%
Low Price Target
103.67BRL
Spread / Lowest Target
-3.52%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
AA